What's new this week?
In an exclusive interview with Dr Espen Basmo Ellingsen, he discusses immuno-oncology innovations which are redefining cancer treatment in 2024. These include anticipated breakthroughs, collaborative endeavours, and personalised strategies that promise to elevate the effectiveness and durability of immuno-oncology interventions. Read further here...
Discover more from scientists at Northwestern Medicine who have demonstrated that RNA interference could have a crucial role in the onset and development of Alzheimer’s disease (AD).
For the first time, researchers have identified short strands of toxic RNAs that contribute to brain cell death and DNA damage in Alzheimer’s and aged brains, and that during ageing, short strands of protective RNAs decrease.
In this article, we explore mechanisms underlying pioneer TF-mediated gene repression. This new study, researchers have made surprising and important findings that may influence organoid and cell reprogramming studies. Click here to find out more.
Researchers have made the discovery that HIV capsids are importin-like transporters, which could be exploited for improved AIDS therapies.
Read more on how new immunological pathways are now treating bone tumours, as researchers have observed significant upregulation of Siglec-15 in the tumour microenvironment in bone tumour samples from breast cancer patients.
TRENDING THIS WEEK
Read more on the advancements within stem cell research in our inaugural report. You'll discover the latest advancements in the field, whilst also hear from many experts including Dr Andy Bader, Dr Kimberley Rockley and Professor Alan Trounson AO.
In this report, we further look at human derived induced pluripotent stem cells (hiPSCs) which have revolutionised research and are increasingly used for toxicology screening and disease modelling.
This article highlights the features of advanced flow cytometry, such as assay miniaturization and automation capabilities, and demonstrates how it can dramatically increase throughput, whilst making it easier to obtain biologically relevant insights. Data may be created and stored in compliance with the requirements of 21 CFR Part 11.
Click here to register now and read more.
In this application note, Quantum-Si’s discusses their Next-Generation Protein Sequencing technology on Platinum?, which rapidly distinguishes SARS-CoV-2 variants based on amino acid sequence. Read more here.
领英推荐
WHAT TO READ
In this article, Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment. Read more >>>
Download this article to hear more from Roy Maute (Pheast Therapeutics), as he reveals his company’s promising drug candidate and explains why they have focused on their chosen target.
Discover how Pheast Therapeutics is developing macrophage-focused immunotherapies to treat cancer. The company’s lead programme is targeting CD24, an immune inhibitory signal that is hijacked by cancer to suppress immune attack. Pheast’s drug candidate, PHST001, blocks CD24, thereby allowing immune cells, including macrophages, to attack the cancer.
Read more from Daniel Kavanagh, PhD, RAC , as he discusses how monoclonal antibodies are limited by their ability to only recognise tumour antigens expressed on the outside surface of a cell.
He explains how investigational genetically engineered medicinal products are leveraging T-cell receptors to allow the immune system to monitor events inside cells, greatly expanding potential immune targets for treating cancer and other diseases.
WHAT TO WATCH
There is still time to sign up for our free Eurofins Discovery webinar. Discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology. Register now.
Our latest webinar in cooperation with Bio Rad Laboratories, is proving very popular. So register now to secure your spot and learn how the challenges with using certain viral vectors in gene therapy has advanced the development of a new generation of precise vectors with sustainable effects.
Expert will also explain the limitations of existing vectors and how these can be overcome using modified recombinant non-replicative herpes simplex virus-1 (HSV-1) vectors. These vectors have potential to expand future applications for gene therapy. Register now >>>
WHAT TO LISTEN TO
Our podcast is back! We are kicking off this year's with how to navigate research insights and projections for the field in 2024 in neuroscience in collaboration with Molecular Devices.
In this episode, we want to find out what are the most exciting and recent advancements in neuroscience, setting the stage for the future.
To listen, click here!
SIGN UP FOR FREE
Sign up here to stay ahead of all the latest breaking news, expert insights and the newest trends in global drug discovery.
Drug Target Review is an essential multimedia resource which is trusted and recognised globally of researchers and scientific leaders who cover the most up-to-date innovations, and cutting edge technologies in the industry.